Liver imaging with MRE (MR Touch) and IDEAL IQ. (A,F) In-phase; (B,G)...
Liver imaging with MRE (MR Touch) and IDEAL IQ. (A,F) In-phase; (B,G) out-of-phase; (C,H) IDEAL IQ; (C) fat fraction 9%, (H) fat fraction 0.6-2.6%; (D,I) MRE and T2w SSFSE fused images; and (E,J) MRE wave images

Imaging in tandem

MRE plus Fib-4 jointly detect liver fibrosis

Rather than using techniques separately, researchers have determined that coupling image-based and serum-based biomarkers achieves a higher diagnostic accuracy in detecting stage two liver fibrosis, or above.

Report: Mark Nicholls

The study team, from the NAFLD Research Center, University of California at San Diego (UCSD), and colleagues at Yokohama City University in Japan, used magnetic resonance elastography (MRE) in tandem with the serum-based Fib-4 clinical prediction rule. Their aim was to decide whether MRE alone, or combined with Fib-4, may be used for non-invasive identification of candidates for pharmacologic therapy among well-characterised patients with non-alcoholic fatty liver disease (NAFLD). Their findings were presented virtually at the Digital International Liver Congress 2020 at the end of August by Jinho Jung of the UCSD NAFLD Research Center.

portrait of jinho jung
Jinho Jung is a researcher at the University of California, at San Diego NAFLD Research Center

NAFLD is estimated to have a global prevalence of 25% and NAFLD patients with stage two fibrosis, or higher, have a significantly increased risk of progression to cirrhosis and liver-related mortality. The gold standard for determining whether a patient is a candidate for pharmacologic therapy is liver biopsy, but this has limitations in terms of variability and discomfort.

Given the global burden of NAFLD, Jung said that liver biopsy assessment to decide candidacy for treatment of non-alcoholic steatohepatitis (NASH) related fibrosis is impractical. ‘Therefore,’ he added, ‘there is an unmet need in the pathologic testing arena to accurately identify each fibrosis patient in a non-invasive manner with a high positive predictive value.’

There are currently some non-invasive diagnostic tests for detection of liver fibrosis, with image-based biomarkers such as Magnetic Resonance Elastography (MRE), Vibration Controlled Transient Elastography (VCTE), Sheer Wave Elastography (SWE) and Acoustic Force Radiation Impulse (ARFI). In addition, serum-based biomarkers include Fibrosis 4 (Fib-4), NAFLD Fibrosis score, Enhanced Liver Fibrosis score (ELF) and Fibrospect II. A combination of two unrelated biomarkers, such as image-based and serum-based biomarkers, has been proposed for staging of liver fibrosis and within the context of NAFLD, promising results have been shown to detect patients with advanced fibrosis or stage three fibrosis or higher.

Limited data

However, there are limited data on whether this data or clinical prediction rule can be applied to stage two fibrosis or higher patients and its cut points. To explore this, the – ‘Utility of magnetic resonance elastography in accurate identification of candidates for pharmacologic treatment of NASH related fibrosis: a prospective cohort study’ – aimed to examine whether MRE alone, or in combination of Fib-4, may be used for non-invasive identification of candidates for pharmacologic therapy among well characterised patients with NAFLD with liver biopsy assessment using NASH CRN histologic scoring system as the reference standard.

Findings, which underlined the value of MRE in this context, were validated in a geographically and ethnically diverse external independent validation cohort with collaborators in Yokohama.

The UCSD cohort of 238 patients with a range of ethnicities had 170 with stage 0-1 and 68 had fibrosis stage two or higher. The validation cohort in Japan recruited 222 patients with stage 0-1 and 138 fibrosis stage two or higher. Jung said: ‘We found that MRE is more accurate than routinely available current prediction rule Fib-4 in detecting stage two fibrosis or above. The difference was clinically and statistically significant.’

Positive predictive value

portrait of rohit loomba
Professor Rohit Loomba is Director of the NAFLD Research Center

Combining MRE with FIB-4 (MRE≥3.3kPa and FIB-4≥1.6) to develop a clinical prediction rule to rule in ≥stage two fibrosis patients showed a positive predictive value (PPV) of 97.1% in the UCSD-NAFLD cohort, and remained significant at 91.0% in the Japan-NAFLD cohort. It is important to note that the cut-points were determined through UCSD-NAFLD cohort and then were validated in the Japan-NAFLD cohort. ‘By coupling MRE and Fib-4 we could achieve higher diagnostic accuracy compared to MRE and Fib-4 alone,’ said Jung. ‘With the cohort being geographically and ethnically diverse, this stresses the clinical applicability of these results in a western and eastern population.’

He acknowledged that there are caveats and limitations to the findings and the findings are only recommended for usage in hepatology clinic settings to rule in patients for pharmacologic treatments. ‘As cut points may be different in primary care settings,’ he said, ‘further study needs to be done in a primary care or diabetes clinic.’

Jung concluded that this study – led by Professor Rohit Loomba, Director, NAFLD Research Center – will serve as a clinical prediction rule to give a high positive corrective value for clinicians to rule in patients to reduce the burden of patients for avoidable risk of liver biopsy.


Profiles:

Jinho Jung is a researcher at the University of California, at San Diego NAFLD Research Center, with specific interests in various aspects of NAFLD, including non-invasive imaging, biomarkers and clinical trial design.

Rohit Loomba is Director of the NAFLD Research Center and leader of the study.

01.12.2020

Read all latest stories

Related articles

Photo

CT, MRI, X-ray, AI, PACS, endoscopy, ultrasound

Fujifilm Healthcare acquires Hitachi Diagnostic Imaging, presents new portfolio

At a virtual European event, Fujifilm Healthcare Europe presented a complete and integrated portfolio of diagnostic products and services, including CT, MRI, X-ray, AI, PACS, endoscopy and ultrasound…

Photo

Expanding potential

Low-field MRI: Less is more

Currently, two opposing trends can be observed in MRI: on the one hand 1.5T scanners are increasingly replaced by 3T scanners for standard clinical MRI applications. On the other hand scanners with…

Photo

Imaging with benefits

Low-field MRI: good quality images, few artefacts and high patient comfort

Low-field MRI is the flavour of the season after several 1.5T models were launched. The major advantages of this technology are a relatively low purchasing price and operating costs and few artefacts…

Related products

Agfa HealthCare – DR 100e

Mobile DR

Agfa HealthCare – DR 100e

Agfa HealthCare
allMRI GmbH – Foldable MRI wheelchair

Accessories / Complementary systems

allMRI GmbH – Foldable MRI wheelchair

allMRI GmbH
allMRI GmbH · Mobile MRI procedure lamp

Accessories/ Complementary Systems

allMRI GmbH · Mobile MRI procedure lamp

allMRI GmbH
allMRI GmbH – MRI doppler ultrasound gating device

Accessories/ Complementary Systems

allMRI GmbH – MRI doppler ultrasound gating device

allMRI GmbH
allMRI GmbH – MRI safe metal free cleaning tool set

Accessories/ Complementary Systems

allMRI GmbH – MRI safe metal free cleaning tool set

allMRI GmbH
Canon – Advanced intelligent Clear-IQ Engine for MR

Artificial Intelligence

Canon – Advanced intelligent Clear-IQ Engine for MR

Canon Medical Systems Europe B.V.
Subscribe to Newsletter